Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Background Gastric cancer (GC) is a heterogenous disease consisted of several subtypes
with distinct molecular traits. The clinical implication of molecular classification has been …

Purpose Gastric cancer (GC) is the third-leading cause of cancer-related deaths. Several
pivotal clinical trials of adjuvant treatments were performed during the previous decade; …

Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-
third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study …

Background Gastric cancer (GC) is a major health problem worldwide, with high prevalence
and mortality. The present GC staging system provides inadequate prognostic information …

Rationale: The prognosis of gastric cancer (GC) patients is poor, and there is limited
therapeutic efficacy due to genetic heterogeneity and difficulty in early-stage screening …

Gastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical
treatment decisions are mostly made based on the extent of the tumor and its anatomy, such …

Gastric cancer (GC) is a heterogeneous disease and a leading cause of cancer-related
deaths. Discovering robust, clinically relevant molecular classifications is critical for guiding …

Background Adjuvant chemotherapy after surgery improves survival of patients with stage II–
III, resectable gastric cancer. However, the overall survival benefit observed after adjuvant …

Opinion statement Gastric cancer is a heterogenous cancer, which may be classified into
several distinct subtypes based on pathology and epidemiology, each with different initiating …